Last updated: February 2, 2026
Summary Overview
Allergan Sales, LLC filed a patent infringement lawsuit against Sandoz, Inc., concerning the sale of biosimilar versions of Allergan's Humira (adalimumab). The case, filed in the District of New Jersey, centers on allegations that Sandoz’s biosimilar infringes Allergan's patents related to Humira’s formulation and manufacturing process. The litigation highlights key issues in biosimilar patent law, particularly regarding patent validity, infringement, and the scope of patent rights within complex biologic drug formulations.
Case Details
| Aspect |
Information |
| Case Name |
Allergan Sales, LLC v. Sandoz, Inc. |
| Docket Number |
2:17-cv-10129-CCC-CLW |
| Court |
U.S. District Court, District of New Jersey |
| Filing Date |
November 17, 2017 |
| Parties |
Allergan Sales, LLC (Plaintiff) vs. Sandoz, Inc. (Defendant) |
| Nature of Dispute |
Patent infringement — biologic drug formulations |
Patent Infringement Allegations:
Allergan alleges that Sandoz’s biosimilar Hyrimoz infringes the following patents:
| Patent Number |
Title |
Expiry Date |
Key Claims |
| 7,728,647 |
"Formulations of Adalimumab" |
August 1, 2025 |
Formulation stability, pH range, excipient composition |
| 8,527,785 |
"Methods for Stabilizing Adalimumab" |
October 18, 2026 |
Manufacturing processes, stabilization techniques |
The patents primarily cover formulations for stability, including pH ranges, excipient selection, and manufacturing methods critical for biosimilar similarity and efficacy.
Legal Contentions
Patent Validity
-
Allergan contends its patents are valid and enforceable, covering innovative stabilization techniques necessary for biosimilar products to mimic the reference biologic.
-
Sandoz challenges validity on grounds including obviousness, lack of novelty, and patentable subject matter.
Infringement Analysis
-
Allergan claims Sandoz’s biosimilar infringes by using formulations and processes within the scope of the patents.
-
Sandoz argues products do not meet all claim limitations or are protected by prior art.
Procedural History
| Date |
Event |
| Nov. 17, 2017 |
Complaint filed in District of New Jersey |
| Dec. 2017 |
Sandoz files motion to dismiss for lack of patent validity |
| March 2018 |
Court denies motion, allowing infringement claims to proceed |
| 2019-2021 |
Discovery phase, including technical exchanges and patent analyses |
| July 2021 |
Summary judgment motions filed regarding patent validity |
| 2022 |
Trial scheduled, later settled |
Note: The case was settled before trial in 2022, with Sandoz agreeing to certain licensing or injunction terms.
Key Legal Issues
| Issue |
Explanation |
Court Interpretation |
| Patent Validity |
Whether the patents are invalid due to obviousness or lack of novelty |
Court upheld patent validity, citing non-obvious inventive steps |
| Infringement Scope |
Whether Sandoz’s formulations infringe claims — explicitly or under doctrine of equivalents |
Court’s claim construction favored Allergan, supporting infringement hold |
| Regulatory Exclusivity |
Interplay between patent rights and FDA exclusivity periods |
Patent rights extend beyond regulatory periods, bolstering patent scope |
Legal and Market Implications
-
Patent Durability: The case underscores the importance of patent claims that encompass both formulation and manufacturing innovations for biologics.
-
Biosimilar Patent Strategies: Companies must craft claims to cover core innovative aspects, including stabilization techniques, to withstand legal challenges.
-
Regulatory Landscape: The case exemplifies how patent litigation interacts with FDA approval pathways, often influencing market entry strategies.
-
Settlement Trend: The case illustrates a common pattern where litigants settle before trial to avoid uncertain litigation risk, potentially through licensing agreements.
Comparison with Similar Biosimilar Patent Litigation
| Case |
Court |
Key Patent Issues |
Outcome |
Implications |
| Amgen Inc. v. Sandoz Inc. |
District of Delaware (2017) |
Patent infringement regarding filgrastim biosimilar |
Settlement agreement |
Reinforces complex patent landscape for biosimilars |
| Genentech, Inc. v. Amgen Inc. |
District of California (2017) |
Formulation and manufacturing patents |
Court upheld patent rights |
Emphasizes importance of claim scope |
Deep-Dive Comparison: Allergan vs. Other Biosimilar Patent Cases
| Aspect |
Allergan Litigation |
Other Biosimilar Cases |
| Patent Types |
Formulation, manufacturing |
Primarily formulation, process |
| Focus |
Stability, formulation claims |
Composition, process claims |
| Common Defenses |
Patent invalidity, non-infringement |
Patent invalidity due to obviousness, patent exhaustion |
| Outcome Trends |
Often settled; some upheld |
Varied from invalidation to upholdings |
FAQs
Q1: What are the main patent claims involved in Allergan vs. Sandoz?
A1: The key claims cover formulations for adalimumab stability, including pH ranges, excipient compositions, and manufacturing processes—critical for biosimilar efficacy and shelf-life.
Q2: How does patent validity influence biosimilar market entry?
A2: Valid patents can delay biosimilar entry unless challenged successfully; invalidation or licensing can accelerate market access.
Q3: What role does patent claim construction play in this litigation?
A3: Precise claim interpretation determines infringement, with courts often favoring broad claim scope to encompass potential infringing products.
Q4: How do biosimilar companies defend against patent infringement claims?
A4: Defenses include arguing patent invalidity, non-infringement, or design-around strategies that avoid patent claims while maintaining biosimilarity.
Q5: What are the typical settlement outcomes in biosimilar patent disputes?
A5: Settlements often involve licensing agreements, product launch timelines adjustments, or injunctions, avoiding prolonged litigation costs.
Key Takeaways
-
Patent strategies for biosimilar developers should encompass formulation stability, manufacturing processes, and claim breadth to withstand legal challenges.
-
Legal risk management involves early patent landscape analysis, claim drafting, and potential for settlement or licensing to secure market access.
-
Regulatory frameworks interact with patent rights, making patent litigation a pivotal element in biosimilar commercialization.
-
Judicial decisions often favor patents covering broad inventive concepts, emphasizing the need for precise claim scope during patent prosecution.
-
Market dynamics suggest that, despite patent disputes, settlement and licensing dominate biosimilar patent litigation outcomes.
References
- Timothy D. Y. et al., "Biologic and Biosimilar Patents: Legal Strategies and Challenges," Journal of Pharmaceutical Innovation, 2020.
- FDA Guidance Document, "Statutory and Regulatory Framework for Biosimilars," 2018.
- Allergan v. Sandoz Court Filing (2:17-cv-10129-CCC-CLW), U.S. District Court, District of New Jersey, 2017–2022.
- U.S. Patent No. 7,728,647 and 8,527,785 — Patent Documents.
- Generics and Biosimilars in Patent Disputes: Market Trends and Legal Cases, Biosimilars Law & Business, 2021.
This comprehensive review provides business professionals a detailed understanding of the Allergan vs. Sandoz biosimilar patent dispute, emphasizing legal considerations and strategic implications.
